Infinity: Duvelisi Shows High Clinical Activity In High-Risk CLL Patients

(RTTNews) - Infinity Pharmaceuticals, Inc. (INFI) announced new clinical data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with treatment-naïve chronic lymphocytic leukemia, a potentially fatal hematologic malignancy. The company said the data from the Phase 1 study showed that duvelisib was highly active in this patient population cohort, with an overall response rate of 88 percent, including 15 partial responses among 17 efficacy evaluable patients.

Infinity also announced new translational data demonstrating that treatment with duvelisib resulted in a decrease in key mediators known to be involved in the communication between chronic lymphocytic leukemia cells and the tumor microenvironment. The company said these data further support the investigation of dual inhibition of PI3K-delta and PI3K-gamma with duvelisib as a therapeutic strategy for the treatment of chronic lymphocytic leukemia.